Quick Answer
Aligos Therapeutics, Inc. reported Total Assets of $88.53 million for fiscal year 2025.
Aligos Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $88.53M | +26.3% |
| 2024 | $70.09M | -53.7% |
| 2023 | $151.53M | +3.3% |
| 2022 | $146.69M | -37.7% |
| 2021 | $235.37M | -11.3% |
| 2020 | $265.30M | +81.1% |
| 2019 | $146.52M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $109.76M | +24.1% | -18.5% |
| June 30, 2025 | $134.71M | +23.8% | -10.6% |
| March 31, 2025 | $150.70M | +17.8% | +115.0% |
| December 31, 2024 | $70.09M | -53.7% | -20.7% |
| September 30, 2024 | $88.43M | +3.0% | -18.7% |
| June 30, 2024 | $108.81M | +2.5% | -14.9% |
| March 31, 2024 | $127.90M | +5.1% | -15.6% |
| December 31, 2023 | $151.53M | +3.3% | +76.5% |
- Aligos Therapeutics, Inc. showed an increase of +26.3% in Total Assets compared to the prior fiscal year.
- Over the 2019–2025 period, Aligos Therapeutics, Inc.’s total assets has declined by 39.6% (from $146.52 million to $88.53 million).
- The most recent figure is from Aligos Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: